Lipoxin B4 (LXB4) plays a significant role in the resolution of inflammation and has potential therapeutic applications in various inflammatory and autoimmune diseases. It is particularly effective in modulating immune responses by promoting the clearance of inflammatory cells and reducing the production of pro-inflammatory mediators. In conditions such as asthma, rheumatoid arthritis, and inflammatory bowel disease, LXB4 helps to restore tissue homeostasis and prevent chronic inflammation. Additionally, it has shown promise in enhancing wound healing and tissue repair by stimulating the regeneration of damaged cells and reducing fibrosis. Research is ongoing to explore its use in treating cardiovascular diseases, where it may help mitigate inflammation-related damage to blood vessels. The ability of LXB4 to resolve inflammation without suppressing the immune system makes it a valuable candidate for developing novel anti-inflammatory therapies.